Swedish Alzheimer patients have grown tired of waiting and traveled abroad to receive treatment for the disease in other countries where it is approved, according to official sources. This has led to Swedes being deprioritized in access to the Alzheimer drug, as reported by major media outlets. The Alzheimer drug is approved within the EU, according to major media reports, but Sweden has not yet made a subsidy decision.
The handling of the subsidy for the Alzheimer drug is criticized, including by the patient association Alzheimerfonden, which co-financed the research behind the medicine, according to official sources. Health economics researchers have questioned how the authorities have handled the subsidy decision, which has not yet been made, despite one year passing since the European approval, according to official sources. Authorities have not provided reasons or a timeline for the subsidy decision.
The specific criticisms from health economics researchers regarding the handling remain unclear.